Evidence map›Paper›PMID 39216831›Full record

ArticleThe Journal of infection2024

IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C.

Thomas R O'Brien, David J Witt, Varun Saxena, Kerry Grace Morrissey, Sabrina Chen, Francine S Baker, Ludmila Prokunina-Olsson, Ruth M Pfeiffer, Jennifer B Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas R O'BrienInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: obrient@mail.nih.gov.
David J WittKaiser Permanente San Rafael Medical Center, San Rafael, CA, United States. Electronic address: dwdw200@gmail.com.
Varun SaxenaKaiser Permanente South San Francisco Medical Center, South San Francisco, CA, United States; University of California San Francisco, San Francisco, CA, United States. Electronic address: Varun.Saxena@kp.org.
Kerry Grace MorrisseyWestat, Rockville, MD, United States. Electronic address: kerrygracemorrissey@westat.com.
Sabrina ChenInformation Management Services, Inc, Calverton, MD, United States. Electronic address: ChenS@imsweb.com.
Francine S BakerInfections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: frncnbaker@gmail.com.
Ludmila Prokunina-OlssonLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: prokuninal@mail.nih.gov.
Ruth M PfeifferBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States. Electronic address: pfeiffer@mail.nih.gov.
Jennifer B LaiKaiser Permanente San Rafael Medical Center, San Rafael, CA, United States. Electronic address: jennifer.b.lai@kp.org.

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

backgroundShorter duration therapy for hepatitis C virus (HCV) infection might reduce treatment costs and increase the number of patients treated and cured. We determined factors associated with treatment response after an 8-week sofosbuvir-based therapy and developed a simple model to predict an individual's likelihood of treatment success.

methodsAmong 2907 patients who received ledipasvir/sofosbuvir for 8 weeks, we determined failure rates by demographic and clinical characteristics, and IFNL4-∆G/TT genotype. We estimated the average IFNL4 genotype-related treatment failure rate in major ancestry groups by applying our IFNL4 genotype results to genotype distributions from reference populations. We created a treatment response model based on three personal characteristics.

resultsOverall, 4.4% of the patients failed treatment. We observed significantly lower failure rates for persons <50 years (1.6%), females (2.6%), those carrying the IFNL4-TT/TT genotype (1.8%), those with HCV RNA <5.8 log

conclusionApplying this algorithm at the point-of-care might facilitate HCV elimination, especially in low- and middle-income countries.

Indexed as

Antiviral AgentsGenotypeHepacivirusHepatitis C, ChronicInterleukinsSofosbuvirAdultAgedBenzimidazolesFemaleFluorenesHumansInterferon LambdaMaleMiddle AgedTreatment FailureAntiviral AgentsBenzimidazolesFluorenesIFNL4 protein, humanInterferon LambdaInterleukinsledipasvir, sofosbuvir drug combinationSofosbuvirGeneticsHCV eliminationInterferon lambdaPersonalized medicinePublic health

Identifiers

PMID39216831
PMCPMC11490369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.